SNTA (synta pharma)http://www.syntapharma.com/Documents/Synta_ASCO%20Update_Jun...hsp inhibitor, generating investor noise, their second med has one good thing and one negative going for it- (positive- has biomarker that correlates with disease progress/regression ... negative- novel mechanism).results for the hsp inhibitor due in 2013, though interim in july 2012.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra